Risk factors related to pleural empyema after talc slurry pleurodesis.


Journal

Clinics (Sao Paulo, Brazil)
ISSN: 1980-5322
Titre abrégé: Clinics (Sao Paulo)
Pays: United States
ID NLM: 101244734

Informations de publication

Date de publication:
2022
Historique:
received: 02 04 2022
revised: 29 06 2022
accepted: 03 08 2022
entrez: 30 8 2022
pubmed: 31 8 2022
medline: 3 9 2022
Statut: epublish

Résumé

Empyema is a complication of talc-pleurodesis that may lead to further surgical intervention and death. Therefore, the present study's objective was to identify the risk factors for the development of post-pleurodesis empyema after talc slurry pleurodesis in order to better select patients for this procedure and minimize its morbidity. Patients with malignant pleural effusion who underwent talc slurry pleurodesis at the present institution from January 2018 to January 2020 were retrospectively analyzed. Post-pleurodesis empyema was defined as pleural infection up to 30 days after pleurodesis. Using Cox regression analysis, significant prognostic factors for the development of empyema were examined. Of the 86 patients identified for inclusion in the study, 62 were women (72%). Their mean age was 56.3±12.6 years. The median pleural drainage time was 9 days, and 20 patients (23.3%) developed empyema. In the univariate analysis, both drainage time (p = 0.038) and the use of antibiotics prior to pleurodesis (p < 0.001) were risk factors for pleural empyema. Multivariate analysis also identified the use of antibiotics as an independent risk factor (Odds Ratio [OR] 9.81; 95% Confidence Interval [95% CI] 2.87‒33.54). Although the pulmonary expansion was not associated with empyema in the multivariate analysis, patients with less than 50% pulmonary expansion had a 4.5-times increased risk of empyema (95% CI 0.90‒22.86; p = 0.067), and patients with 50‒70% pulmonary expansion had a 3.8-times increased risk of empyema (95% CI 0.98‒15; p = 0.053) after pleurodesis. The study suggests that antibiotic therapy prior to talc slurry pleurodesis may increase the risk of developing empyema. Furthermore, pleurodesis should be considered with caution in patients with long-duration chest tube placement and incomplete lung expansion.

Identifiants

pubmed: 36041370
pii: S1807-5932(22)03299-9
doi: 10.1016/j.clinsp.2022.100098
pmc: PMC9440271
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Talc 14807-96-6

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100098

Informations de copyright

Copyright © 2022 HCFMUSP. Published by Elsevier España, S.L.U. All rights reserved.

Déclaration de conflit d'intérêts

Conflicts of interest The authors declare no conflicts of interest.

Références

Thorax. 2016 Oct;71(10):964-6
pubmed: 27418604
J Surg Oncol. 2018 Jun;117(7):1556-1562
pubmed: 29572835
Chest. 2017 Apr;151(4):845-854
pubmed: 27876589
Clinics (Sao Paulo). 2022 Jun 18;77:100063
pubmed: 35728443
J Thorac Cardiovasc Surg. 2017 Jun;153(6):e129-e146
pubmed: 28274565
N Engl J Med. 2005 Mar 3;352(9):865-74
pubmed: 15745977
Respiration. 2015;90(5):369-75
pubmed: 26439936
Am J Respir Crit Care Med. 2018 Oct 1;198(7):839-849
pubmed: 30272503
Cochrane Database Syst Rev. 2004;(1):CD002916
pubmed: 14973997
Curr Opin Pulm Med. 2000 Jul;6(4):255-8
pubmed: 10912629
Chest. 2005 Mar;127(3):909-15
pubmed: 15764775
Clinics (Sao Paulo). 2011;66(2):211-6
pubmed: 21484035
Chest. 2001 Mar;119(3):801-6
pubmed: 11243960

Auteurs

Paula Duarte D'Ambrosio (PD)

Instituto do Câncer do Estado de São Paulo (ICESP), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil. Electronic address: pauladuartedambrosio94@gmail.com.

Pedro Henrique Xavier Nabuco de Araújo (PHXN)

Instituto do Câncer do Estado de São Paulo (ICESP), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

Eserval Rocha Junior (ER)

Instituto do Câncer do Estado de São Paulo (ICESP), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

Mauro Razuk Filho (MR)

Instituto do Câncer do Estado de São Paulo (ICESP), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

Paulo Manuel Pêgo-Fernandes (PM)

Instituto do Coração, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

Ricardo Mingarini Terra (RM)

Instituto do Câncer do Estado de São Paulo (ICESP), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH